SPHDF Stock - Santhera Pharmaceuticals Holding AG
Unlock GoAI Insights for SPHDF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $39.12M | $103.41M | $7.47M | $-1,595,000 | $15.01M |
| Gross Profit | $22.96M | $100.18M | $3.88M | $-5,362,000 | $4.58M |
| Gross Margin | 58.7% | 96.9% | 51.9% | 336.2% | 30.5% |
| Operating Income | $-33,383,000 | $68.84M | $-51,976,000 | $-56,888,000 | $-53,076,000 |
| Net Income | $-41,974,000 | $54.78M | $-71,076,000 | $-55,526,000 | $-67,659,000 |
| Net Margin | -107.3% | 53.0% | -951.1% | 3481.3% | -450.8% |
| EPS | $-3.69 | $5.18 | $-11.67 | $-16.25 | $-50.81 |
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
Visit WebsiteEarnings History & Surprises
SPHDFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 27, 2026 | — | — | — | — |
Q2 2025 | Apr 29, 2025 | — | $-2.58 | — | — |
Q3 2024 | Sep 12, 2024 | — | $-1.50 | — | — |
Q2 2024 | Jun 18, 2024 | — | $-0.75 | — | — |
Q2 2024 | Apr 25, 2024 | — | $8.18 | — | — |
Q3 2023 | Sep 30, 2023 | — | $3.99 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-2.33 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-1.14 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-6.95 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-3.22 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-5.47 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-7.72 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-9.99 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-26.03 | — | — |
Q3 2020 | Sep 8, 2020 | — | — | — | — |
Q2 2020 | Jun 30, 2020 | — | $-29.40 | — | — |
Q1 2020 | Mar 24, 2020 | — | — | — | — |
Q4 2019 | Dec 31, 2019 | — | $7.28 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-25.23 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-39.90 | — | — |
Latest News
Frequently Asked Questions about SPHDF
What is SPHDF's current stock price?
What is the analyst price target for SPHDF?
What sector is Santhera Pharmaceuticals Holding AG in?
What is SPHDF's market cap?
Does SPHDF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SPHDF for comparison